|
Clinical Trials for Squamous Cell Carcinoma |
|
|
|
Exploratory safety study of an intravenous infusion of a novel therapeutic agent for the treatment of melanoma, osteosarcoma, soft tissue sarcoma or squamous cell carcinoma in dogs: A multi-center study
Eligibility Requirements
To qualify for enrollment in this study, dogs must have:
• Histologic or cytologic diagnosis of cancer (biopsy or needle aspirate)
• There is at least 1 tumor (melanoma, osteosarcoma, soft tissue sarcoma, or squamous cell carcinoma) which can be measured (minimum 1 cm in diameter);
• Generally feeling well (i.e. eating, drinking, ambulating on their own, etc.)
• No evidence of an active bacterial infection requiring antibiotics (other than topical medications) in the past 7 days;
• No anti-cancer therapy within the past 21 days. This includes chemotherapy, radiation therapy, prednisone (or other forms of corticosteroids), and immunotherapy; No tumors where abscess (infection) would result in major symptoms
Study Objective
The primary objective of this multi-institutional exploratory study is to describe the safety and efficacy of three dosages of an intravenous infusion of C. novyi-NT spores, with and without concomitant therapy, in dogs with spontaneous tumors.
Compensation
The study sponsor will pay for therapeutic agent, diagnostic tests, and follow-up evaluations. In the event that side effects are noted and attributed to the therapeutic agent, the study will pay for medical management of the side effects. Please click on the link for more details.
Location of Trial
Columbus, OH
More information
Feline Oral Squamous Cell Carcinoma
Eligibility Requirements
• click on link for details.
Study Objective
Examine the efficacy of toceranib phosphate (Palladia) as a primary and/or adjuvant agent in the treatment of feline oral squamous cell carcinoma Oral squamous cell carcinomas account for approximately 90% of feline oral tumors and at this time there are no consistently effective treatment options. These tumors are biologically aggressive and locally invasive. Median survival time in untreated cases is approximately 60 days. Radiation therapy or chemotherapy used alone is generally ineffective. Accelerated radiation protocols appear to have some efficacy. The combination of full course radiation therapy with radiation sensitizers or chemotherapy improves the number of cats that respond to therapy, but overall survival times remain in the 4-6 month range. Unfortunately, this treatment option comes with significant expense. Palladia is a tyrosine kinase inhibitor that affects the development of blood vessels by targeting receptor tyrosine kinases within tumors. By blocking the signaling of these pathways tumor growth can be slowed. The presence of these receptors (VEGF and VEGFRs) has been well documented in human oral squamous cell carcinomas. This has not been evaluated yet in feline tumors. Evidence continues to accumulate indicating that Palladia can also increase the sensitivity of tumor cells to radiation therapy and that Palladia has some primary activity in feline oral squamous cell carcinomas. Because of these effects, clinical investigation of Palladia as therapy for feline oral squamous cell carcinoma alone or in combination with radiation therapy is indicated.
Compensation
Your cat will receive the drug at no cost. We expect that treatment with Palladia will benefit some cats with oral squamous cell carcinoma by increasing response rates and prolonging disease free intervals and overall survival times. Please click on the link for more details.
Location of Trial
Auburn, AL
More information
Clinical Trial for Dogs with Squamous Cell Carcinoma
Eligibility Requirements
• Inclusion criteria for participation in this clinical trial includes:
• Any age, weight, breed or sex, diagnosed with squamous cell carcinoma
• A life expectancy of more than 1 month
• Owner consent prior to enrollment in the study
• Clinically measurable disease. Longest diameter (LD) should be ≥ 20 mm
• Dog with normal neutrophil and platelet counts
• Adequate liver function
• Adequate kidney function
Exclusion criteria for participation in this clinical trial includes:
• A condition that will need treatment with systemic glucocorticoids such as prednisone during the study period (unless this medication has been started at least 2 weeks prior to study enrollment)
• Significant gastrointestinal signs
• Presence of active infection
• Dogs that are currently enrolled in another clinical trial
• Pregnant or lactating dogs
• Any other reason which according to the veterinarian participating in the study, would affect the safety of the dog or severely interfere with study procedures
Study Objective
A maximum of 12 client-owned dogs will be enrolled in this open-label study. All dogs will receive the novel chemotherapeutic. Enrolled patients will have the opportunity to receive a maximum of 4 treatments, each given 3 weeks apart. One week after each treatment, dogs will be seen at the study site for follow-up bloodwork..
Compensation
The cost of the initial consultation with the oncologist will be the responsibility of the owner; however the sponsor will pay for drug, diagnostic tests, and follow-up exams throughout the duration of the study. In the event that side effects are noted and attributed to the study drug, the study will pay for medical management of the side effects. Please click on the link for more details.
Location of Trial
Various Locations (click on link below for details)
More information
Examining the Efficacy of Toceranib Phosphate (Palladia®) as a Primary and/or Adjuvant Agent in the Treatment of Feline Oral Squamous Cell Carcinoma
Eligibility Requirements
• Histologically or cytologically confirmed feline oral squamous cell carcinoma
• Greater than 24 months of age
• Greater than 3.1 kg body weight
• Estimated life expectancy greater than 6 weeks
• Adequate organ function
Study Objective
To identify the activity of toceranib phosphate alone or as a radiation sensitizing agent in the treatment of feline oral squamous cell carcinoma.
Compensation
Owners would assume financial responsibility for the radiation therapy and any associated supportive care. Pfizer would provide the toceranib at no cost to the owner. Informed consent would be given by every owner whose pet is participating in the trial. Please click on the link for more details.
Location of Trial
Tinton Falls, NJ
Columbus, OH
University of Georgia (Athens, Georgia)
More information
Palladia or Palladia plus Radiation Therapy in Cats with Oral Squamous Cell Carcinoma
Eligibility Requirements
• To qualify for enrollment in this study, cats must:
• Have histologically or cytologically confirmed diagnosis of oral SCC
• Have a life expectancy of at least 6 weeks
• Have no evidence of metastatic disease at the time of enrollment
• Have no other serious health problems that are incompatible with the study (as renal, cardiac or hepatic insufficiency)
Study Objective
The purpose of this study is to identify the activity of toceranib phosphate (Palladia) alone or as a radiation sensitizing agent in the treatment of feline oral squamous cell carcinoma.
Compensation
The study will provide Palladia free of cost for duration of study
Client Cost
Owners are responsible for the fees associated with the radiation therapy treatment, recheck visits and tests performed. We expect the cost of radiation therapy to be $2000-$2300 and the cost of each recheck visit to be approximately $80-160. Owners are also responsible for any additional costs that arise from other medications, and the treatment of potential complications during the study. Please click on the link for more details.
Location of Trial
Columbus, OH
More information
Analysis of Palladia Pharmacokinetics and Pharmacodynamics at Non-Label Dosing
Eligibility Requirements
• Have a sarcoma, carcinoma, melanoma or other solid tumor (excluding histiocytic sarcoma and hemangiosarcoma) that has either failed standard therapy or for which the owner declines standard therapy
• Have a life expectancy of approximately 90 days
• Have completed any chemotherapy or radiation therapy at least 2 weeks prior to enrollment
Study Objective
The goal of this study is to determine the pharmacokinetics (blood levels) of Palladia given to dogs with cancer at doses lower than that recommended on the label.
Compensation
Palladia will be provided at no cost during, and 6 months after the completion of the study representing a savings of $1500-3000 to owners. The owner is responsible for all other costs including office visits and bloodwork. Please click on the link for more details.
Location of Trial
Columbus, Ohio
More information
Phase I Clinical Trial of Vinorelbine in Tumor- Bearing Cats
Eligibility Requirements
• Cats with any cytologically or histologically confirmed cancer are eligible.
• They may have measureable or microscopic disease to participate.
• They may have had prior surgery, radiotherapy. and/or chemotherapy. However, there must be at least a four week lapse between any of these treatments and entry into the trial.
• Cats may not receive non-steroidal anti-inflammatory drugs (NSAIDS) or steroids while in the study and must undergo a 72 hours washout period if on NSAIDS or steroids prior to stduy initiation.
• They must have normal organ and bone marrow function and have an expected survival of at least 4 weeks.
• Owners must sign a consent form.
Study Objective
To determine the dose-limiting toxicity and maximum tolerated dosage, to establish a safe starting dosage, and to elucidate treatment-related side effects of Vinorelbine in tumor-bearing cats.
Compensation
ost of intial tests, chemotherapy and follow-up CBC will be reimbursed if the cat qualifies for the study.Assuming the cat tolerates the dosage well, treatments may be continue every other week, off-study, at the owners expense. Complications of chemotherapy will NOT be covered by the study. Please click on link for more details.
Location of Trial
Athens, GA
More information
Study investigating new drug safety and effects on feline oral squamous cell carcinoma
Eligibility Requirements
• Cat must have been diagnosed with oral squamous cell carcinoma with a biopsy
• Owner has opted not to have surgery performe to remove the tumor or pursue other chemotherapy or radiation treatment, either by the veterinarian’s advice or their own choice.
• If the cat previously had surgery to remove the squamous cell carcinoma and the cancer has recurred, the cat is still eligible.
• Cat must have a reasonably good appetite and owner must be willing and able to give oral liquid medication three times per day.
Study Objective
Evaluating the toxicity and efficacy of two polyamine inhibitor drugs, 2-difluoromethylornithine (DFMO) and MQT 1569.
Compensation
This study is partially funded. Please click link for more details.
Location of Trial
Philadelphia, PA
More information
Phase Ib study of GS-424044 in dogs with malignant neoplasia
Eligibility Requirements
• Dogs with advanced solid tumors (mainly carcinomas and sarcomas)
• Dogs with tumor type confirmed by histology (for solid tumors)
• Dogs must weigh at least 10.0kg
• Dogs must be otherwise healthy and at least one year of age.
• Have adequate organ function as specified by standard laboratory tests
Study Objective
The purpose of this study is to investigate a new chemotherapy drug as treatment for dos with malignant tumors.
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Athens, GA
More information
IL-12 gene therapy for enhancing therapeutic efficacy of Bleomycin against oral tumors
Eligibility Requirements
• Dogs must have a histopathological diagnosis of oral SCC, oral melanoma or acanthomatous ameloblastona
• Dogs with local or regional but not systemic metastatic disease are eligible for treatment
• Dogs with anticipated survival time without treatment of more than 2 months
• Dogs CANNOT have any history of clinically significant hepatic and/or renal toxicity.
Study Objective
The objective of this study is to evaluate the clinical response of canine oral SCC, oral melanoma or acanthomatous ameloblastoma treated with combination IL-12 and Bleomycin electrochemotherapy vs. Bleomycin electrochemotherapy or IL-12 electrochemotherapy alone.
Compensation
This study is fully funded if you go to LSU. This study is partially funded if you pursue treatment at VOHC. Please click on LSU link for more details.
Location of Trial
Baton Rouge, LA: More information
Norwalk, CT: More information
Satraplatin for any tumor, including lymphoma
Eligibility Requirements
• Any tumor, including lymphoma confirmed by histopathology or cytology
Study Objective
To determine efficacy of using Satraplatin for various types of cancer using 5mg/m2 daily (orally).
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Columbia, MO
More information
|
| |
|
